Affiliation: University of Stuttgart
Podder B, Guttà C, Rožanc J, Gerlach E, Feoktistova M, Panayotova Dimitrova D, et al
. TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma. Cell Death Differ. 2019;: pubmed publisher
..Overall, our results therefore demonstrate that TAK1 suppresses the susceptibility to RIPK1-dependent cell death and that high expression of TAK1 indicates an increased risk for disease progression in melanoma. ..
Skoko J, Rožanc J, Charles E, Alexopoulos L, Rehm M. Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma. BMC Cell Biol. 2018;19:28 pubmed publisher
..Loss of p53 phosphorylation might be an interesting candidate for a kinetic marker of dasatinib responsiveness in melanoma, pending more comprehensive validation in future studies. ..
Lincoln F, Imig D, Boccellato C, Juric V, Noonan J, Kontermann R, et al
. Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism. Cell Death Dis. 2018;9:1112 pubmed publisher
Crawford N, Salvucci M, Hellwig C, Lincoln F, Mooney R, O Connor C, et al
. Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711. Cell Death Differ. 2018;25:1952-1966 pubmed publisher
Hantusch A, Das K, García Sáez A, Brunner T, Rehm M. Bax retrotranslocation potentiates Bcl-xL's antiapoptotic activity and is essential for switch-like transitions between MOMP competency and resistance. Cell Death Dis. 2018;9:430 pubmed publisher
..Our results therefore identify Bax retrotranslocation by Bcl-xL as an indispensable component of the molecular switch by which Bcl-2 family members govern cellular death decisions. ..